<DOC>
	<DOCNO>NCT02850978</DOCNO>
	<brief_summary>Study assess long-term safety effectiveness Spilolto Japanese patient COPD real-world setting</brief_summary>
	<brief_title>Long-term Use Spiolto Respimat Japanese Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<criteria>Inclusion criterion : Patients diagnose chronic obstructive pulmonary disease ( chronic bronchitis , emphysema ) physician need relief various symptom associate LABA LAMA . Patients prescribed Tio+Olo FDC 5µg/5µg first time Exclusion criterion : Patients register study ( i.e. , reentry patient allow ) . Patients participate registry clinical trial . Patients contraindication Tio+Olo FDC 5µg/5µg define package insert Tio+Olo FDC 5µg/5µg .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>